바이오트로닉코리아

비상장계속사업자

BIOTRONIK Korea Co., Ltd.

김수홍

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

바이오트로닉코리아

Business Reg. No. 2148878065 · CEO 김수홍

I.Investment Overview

Target바이오트로닉코리아 (2148878065)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명바이오트로닉코리아
영문명BIOTRONIK Korea Co., Ltd.
대표자김수홍
사업자등록번호2148878065
법인등록번호1101114602599
설립일2011.06.01

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW468.22021470.12022476.92023346.520241692025
영업이익100M KRW13.2202113.2202248.7202314.220249.42025
순이익100M KRW9.820219.1202241.820239.3202442.32025
Item20252024202320222021
자산총계274.2억원250.2억원239.4억원225.5억원231억원
부채총계121.9억원141.3억원138.4억원163.6억원183.5억원
자본총계152.3억원108.9억원100.9억원61.8억원47.5억원
매출액169억원346.5억원476.9억원470.1억원468.2억원
영업이익9.4억원14.2억원48.7억원13.2억원13.2억원
순이익42.3억원9.3억원41.8억원9.1억원9.8억원

VI.Financial Ratios

FY2025 basis

5.54%

영업이익률

25.04%

순이익률

15.43%

ROA

27.78%

ROE

80.03%

부채비율

55.55%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

바이오트로닉코리아 투심보고서 | Alpha Lenz